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Abstract
The cystic fibrosis transmembrane conductance regulator (CFTR) is an epithelial chloride channel mutated in patients with
cystic fibrosis (CF). The most prevalent CFTR mutation, DF508, blocks folding in the endoplasmic reticulum. Recent work has
shown that some DF508-CFTR channel activity can be recovered by pharmaceutical modulators (‘‘potentiators’’ and
‘‘correctors’’), but DF508-CFTR can still be rapidly degraded via a lysosomal pathway involving the CFTR-associated ligand
(CAL), which binds CFTR via a PDZ interaction domain. We present a study that goes from theory, to new structure-based
computational design algorithms, to computational predictions, to biochemical testing and ultimately to epithelial-cell
validation of novel, effective CAL PDZ inhibitors (called ‘‘stabilizers’’) that rescue DF508-CFTR activity. To design the
‘‘stabilizers’’, we extended our structural ensemble-based computational protein redesign algorithm K to encompass
protein-protein and protein-peptide interactions. The computational predictions achieved high accuracy: all of the top-
predicted peptide inhibitors bound well to CAL. Furthermore, when compared to state-of-the-art CAL inhibitors, our design
methodology achieved higher affinity and increased binding efficiency. The designed inhibitor with the highest affinity for
CAL (kCAL01) binds six-fold more tightly than the previous best hexamer (iCAL35), and 170-fold more tightly than the CFTR
C-terminus. We show that kCAL01 has physiological activity and can rescue chloride efflux in CF patient-derived airway
epithelial cells. Since stabilizers address a different cellular CF defect from potentiators and correctors, our inhibitors provide
an additional therapeutic pathway that can be used in conjunction with current methods.
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Introduction
Protein-peptide interactions (PPIs) are vital for cell signaling,
protein trafficking and localization, gene expression, and many
other biological functions. The PDZ (PSD-95, discs large, zonula
occludens-1) family of proteins forms PPIs that play crucial
physiological roles, including synapse formation [1] and epithelial
cell polarity and proliferation [2]. The common PDZ structural
core generally binds a specific sequence motif at the extreme C-
terminus of its binding partner through b-sheet interactions
(Fig. 1A). Recently, key PPIs have been discovered linking the
trafficking of the cystic fibrosis transmembrane conductance
regulator (CFTR) to PDZ domain containing proteins [3]
(Fig. 1B). Specifically, the PDZ domain of the CFTR-associated
ligand (CAL) binds CFTR, targeting it for lysosomal degradation
and reducing its half-life at the plasma membrane [4,5].
CFTR is an epithelial chloride channel that is mutated in cystic
fibrosis (CF) patients. The most common disease-associated
mutation, DF508-CFTR, is a single amino acid deletion that causes
CFTR misfolding and endoplasmic reticulum-associated (ER)
degradation. There is now evidence that the DF508-CFTR loss of
function can be pharmacologically improved through the use of
‘‘correctors’’ [6] and ‘‘potentiators’’ [7]. Correctors, such as corr-4a
[6,8],workbycorrecting thefoldingdefectofCFTRandpreventing
ER retention of CFTR. Potentiators combat mutant CFTR gating
defects and increase the flow of ions through CFTR channels
present at the cellular membrane. Despite these interventions, the
half-life ofDF508-CFTRinthemembraneisstillreducedcompared
to that of the wild-type protein [9]. However, the CAL-mediated
degradation of DF508-CFTR can be reduced by RNA interference
or by mutagenesis of the CAL PDZ domain, suggesting that a
competitive inhibitor of the CAL binding site could act as a CFTR
‘‘stabilizer’’ and thus ameliorate CF symptoms [3,10]. Since
stabilizers address a different underlying CF defect than correctors
and potentiators, combined application can achieve additive rescue
of DF508-CFTR activity [11].
Since PDZ domains have an inherent affinity for peptides, here
we focus on the use of protein design methods to rationally design
a competitive peptide inhibitor that could serve as a DF508-CFTR
stabilizer. Indeed, the development of successful peptide inhibitor
design tools would provide a means to target a wide variety of PPIs
for both mechanistic and therapeutic applications. Several aspects
of our new K design algorithm (described below) are well suited
to the requirements of this class of problems.
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amino-acid sequences that are compatible with a specific protein
fold. Often, additional functional constraints are applied to the
problem in order to design a protein with a given binding or
catalytic activity. Because protein conformational space is large,
design algorithms often assume a fixed backbone conformation
and reduce side-chain configuration space by using discrete
conformations called rotamers [12–15]. Thus, most current design
methods try to solve the traditional design problem, which can be
defined as: for a given input model (protein structure, rotamer
library, and energy function), find the side chain rotamers that
yield a single, global minimum energy conformation (GMEC) for
the entire protein [16–34]. However, in reality, a protein in
solution exists as a thermodynamic ensemble and not just a single
low-energy structure [35]. Accounting for such ensembles can help
find true native protein structures [36–39]. The design algorithm
we present here, K, takes this into account by computing
Boltzmann-weighted partition functions over structural molecular
ensembles to find provably-accurate approximations to the
binding constant for a protein complex [40,41]. The value of this
approach is reflected in previous applications of the K algorithm
to design a switch in enzyme specificity for an enzyme in the non-
ribosomal peptide synthetase pathway [40] and to predict
resistance mutations for antibiotic targets [42].
As with the established K algorithm, most successful protein
design studies have focused on protein/small molecule systems,
since predicting PPI binding is more challenging than small
molecule binding, due to PPIs’ much larger, flexible, and
energetically shallow binding surfaces. The methodologies that
have been developed to study protein-protein interactions and,
more specifically, PDZ domain interactions, can be divided into
sequence- [43,44] and structure-based [38,45–49] methods.
Sequence-based methods require a large amount of sequence
and binding information for the protein family and do not provide
direct structural information on the modeled interaction. Among
the previous structure-based alternatives, most focus on finding the
single GMEC conformation, although one study suggests that
designing to a set of different backbone conformations can
improve recovery of PDZ domain binding motifs [45]. In addition,
only the work of Altman et al. [46] utilizes provable techniques,
and none use both provable techniques and protein ensembles. In
comparison, the K algorithm is more general, requiring only a
starting template structure and preserving structural information
on the modeled interaction. It also evaluates energy-weighted
ensembles, employs provable guarantees for finding the optimal
sequence, and uses the minimization aware dead-end elimination
(minDEE) pruning criteria [16,41] to permit continuous minimi-
zation of rotamers during the search. As a result, K complements
existing approaches while addressing some of their methodological
limitations. Here we report the development of new extensions to
the K algorithm, enabling the software to design novel PPIs.
Author Summary
Cystic fibrosis (CF) is an inherited disease that causes the
body to produce thick mucus that clogs the lungs and
obstructs the breakdown and absorption of food. The cystic
fibrosis transmembrane conductance regulator (CFTR) is
mutated in CF patients, and the most common mutation
causesthreedefectsinCFTR:misfolding,decreasedfunction,
and rapid degradation. Drugs are currently being studied to
correct the first two CFTR defects, but the problem of rapid
degradation remains. Recently, key protein-protein interac-
tions have beendiscovered thatimplicate the proteinCAL in
CFTR degradation. Here we have developed new compu-
tational protein design algorithms and used them to
successfully predict peptide inhibitors of the CAL-CFTR
interface. Our algorithm uses a structural ensemble-based
evaluation of protein sequences and conformations to
calculate accurate predictions of protein-peptide binding
affinities. The algorithm is general and can be applied to a
wide variety of protein-protein interface designs. All of our
designed inhibitors bound CAL with high affinity. We tested
our top binding peptide and observed that the inhibitor
could successfully rescue CFTR function in CF patient-
derived epithelial cells. Our designed inhibitors provide a
novel therapeutic path which could be used in combination
with existing CF therapeutics for additive benefit.
Figure 1. (A) Structural model of the CAL PDZ domain (green and blue) bound to a CFTR C-terminus mimic (gray) used as input for
computational designs (PDB id: 2LOB). Residues shown in blue were modeled as flexible during the design search. (B) Model of the CFTR
trafficking pathway with PDZ domain containing proteins NHERF1 and CAL. CAL is associated with lysosomal degradation of CFTR, while NHERF1 is
associated with insertion of CFTR into the cell membrane.
doi:10.1371/journal.pcbi.1002477.g001
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inhibitors and validated them in both biochemical and cell-culture
experiments. We present peptide array data which shows that
CAL binds a specific sequence motif, but does not bind all
sequences within that motif. Therefore, it is important that the K
algorithm is able to differentiate the affinities of peptides that share
the motif, rather than just separating motif from non-motif
sequences. Overall, K searched 2166 peptide inhibitor sequences
within the CAL binding motif (approximately 1015 possible
conformations) and generated top-ranked peptides that had up
to a 170-fold improvement in binding to CAL compared to the
wild-type CFTR sequence. The best binder was able to rescue
DF508-CFTR function in human cells.
Materials and Methods
K Algorithm
K computationally searches over peptide amino acid substitutions
(mutations) for a given protein-peptide complex and assigns each
candidate sequencea score,called a K score [40,41]. To compute the
score for a given protein-peptide complex candidate sequence, K
evaluates the low-energy conformations for the sequence and uses
them to compute a Boltzmann-weighted partition function. Parti-
tion functions are computed for each protein binding partner
using rotamer-based ensembles defined as qA~
P
a[A
exp({Ea=RT),
qB~
P
b[B
exp({Eb=RT), qAB~
P
ab[AB
exp({Eab=RT) where qAB is
the partition function for protein A bound to protein B,a n dqA and
qB are the partition functions for the unbound proteins, A and B.T h e
K score is defined as the ratio of partition functions: K~
qAB
qAqB
,
which is an approximation of the protein complex association
constant, KA [41]. Candidate sequences are ranked based on their
K score, where sequences with a higher K score are considered to
have a higher affinity for the target protein.
The K algorithm has been described previously [16,40,41].
Briefly, to calculate a partition function for a given sequence, K
finds low energy conformations by performing a rotamer search as
follows. First, K uses an enhanced version of dead-end elimination
(DEE), minDEE [16,41,50], to prune side-chain rotamers that
provably cannot be part of low-energy structures. Since rigid-
rotamer DEE [34,51] often eliminates rotamers and sequences that
are involved in bona fide low-energy conformations [50], K prunes
rotamers using minDEE, which allows local side-chain rotamer
minimization to relieve clashes that are incorrectly pruned by rigid
rotamer design methods. In order for minDEE to account for
minimization during the rotamer search, it computes energy lower
boundsforeachrotamer pair.Thebranch-and-bound algorithmA
[30] is used to enumerate conformations in gap-free order of their
minimum energy bounds. These conformations are minimized and
their Boltzmann-weighted energy is incorporated into the partition
function. The partition function is computed with respect to the
input model (protein structure, energy function, and rotamer
library), so the accuracy of the partition function is bounded by the
accuracy of the input model. Refer to Fig. 2 to see the general
framework for the K algorithm.
The energy minimization scheme that is used for both the
energy lower bounds computation and the minimization of a full
conformation is similar to previous descriptions [41]. The K
algorithm’s minimization protocol separates a protein’s degrees of
freedom (DOF) into three categories: (1) backbone dihedrals (w
and y angles) (2) side-chain dihedrals (up to four x angles per side
chain) and (3) rigid body rotation and translation (R
3|SO(3)).
The minimization process holds the backbone dihedrals fixed
while allowing the side-chain dihedral and rigid body DOF to
minimize. The minimization over these DOF is performed using
gradient descent. To prevent rotamers from minimizing from one
rotamer to another, each side-chain dihedral was only allowed to
move a maximum of 90 from its modal rotameric value.
Extension of K to Amino Acid Substitutions/Flexibility
on Two Protein Strands
K relies on the mathematically provable guarantees of each of
its steps (Fig. 2) to compute an accurate K score. If we were to use
heuristic steps to find the low energy conformations, it could not
be guaranteed that all the low energy conformations are found and
we would lose the ability to calculate a provably-good e-
approximation (where e is user-defined) to each partition function
for the design system. Because of the provable aspects of K,i fK
makes an errant prediction, we can be certain that it is due to an
inaccuracy in the input model and not a problem (such as
inadequate optimization) with our search algorithm. This makes it
substantially easier to improve the model based on experimental
feedback, as we show in Section S2 of Text S1.
Before applying K to PPI designs, we first had to ensure that
the mathematical framework of K could be extended to cover
larger systems. For large designs such as PPIs, the provable
guarantees of K no longer hold as they did for small design
systems. Specifically, the previous K proofs [41] for intermutation
pruning and guaranteeing the accuracy of the K score, relied on
properties of small molecule design systems that are not true for
PPIs. We now show that it is possible to improve the K algorithm
to maintain these critical provable guarantees. As a result, systems
where both binding partners in the protein complex are flexible or
mutable during the search can be accurately studied using K.
Intermutation pruning uses computed partition functions to truncate
the conformation enumeration process for candidate sequences
whentheywillprovablyfailtoachieveaK scoreclosetothebestK
score.Toshowthatanintermutationpruningcriterion[41]existsfor
PPI design we seek a halting condition for the conformation
enumeration such that we know we have an e-approximation to the
Figure 2. Overview of K Algorithm. The K algorithm searches
over protein sequences and conformations to find the protein
complexes with the best binding constant. K takes an input model
composed of an initial protein structure, a rotamer library to search over
side-chain conformations, and an energy function to evaluate
conformations. Minimization-aware DEE (minDEE) prunes rotamers that
are not part of the lowest energy conformations for a given sequence.
The remaining conformations from minDEE are enumerated in order of
increasing energy lower bounds using A*. Finally, the conformations are
Boltzmann-weighted and used to compute partition functions and
ultimately a K score for each sequence.
doi:10.1371/journal.pcbi.1002477.g002
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observe: K
i §cK
0, where K
i is the K score of the current
sequence, K
0 isthebestscoreobserved sofar,and c is a user-selected
parameter. In the following lemma, n is the number of conforma-
tions in the search that remain to be computed, k is the number of
conformations that have been pruned from the search with DEE, E0
is the lower energy bound on all pruned conformations, R is the
universal gas constant, and T is the temperature. The full partition
function for the protein-protein complex, and unbound proteins are
qAB, qA,a n dqB respectively, while q
AB, q
A,a n dq
B denote the current
calculated value of the partition functions during the computational
search.
Lemma 1. If the lower bound Et on the minimized energy of
the (mz1)
th conformation returned by A satisfies Et§{RT
(ln(ceK
0q
Aq
B{kexp({E0=RT)){lnn), then the partition function
computation can be halted, with q
AB guaranteed to be an e-approximation to
the true partition function, qAB, for a candidate sequence whose score K
i
satisfies K
i §cK
0.
This lemma shows that even when designing for protein-protein
interactions, there exists a sequence pruning criterion during the
K search.
Now we show that we can obtain a provable guarantee on the
accuracy of the K score for each protein conformation. Since
both partition functions are e-approximations, we no longer obtain
an e-approximation to the K score but rather the following:
Lemma 2. When amino acid substitutions (or flexible residues) are
allowed on both strands in the computational design, the computed K score is
a s-approximation to the actual K score, where s~e(2{e).
Since neither of the protein complex partition functions are
calculated fully, the K score approximation is a 2e-approximation
as opposed to the e-approximation for small molecule designs.
This implies that we must compute better partition function
approximations than before to maintain the same level of K score
approximation. Nevertheless, the fact that the K score can still be
provably approximated, confers all the advantages of a provable
algorithm as stated above. The proofs of Lemmas 1 and 2 are
provided in Text S1.
Computational Designs with K
The previously-determined NMR structure of the CAL PDZ
domain bound to the C-terminus of CFTR (PDB ID: 2LOB) was
used to model the binding of CAL to CFTR. To prepare the
protein complex for the computational design, the initial complex
structure was obtained by molecular dynamics refinement of the
NMR structure as described previously [52]. Hydrogens were
added to the structure using Reduce [53]. The CFTR peptide in
the NMR structure was truncated to the six most C-terminal
amino acids. An acetyl group was modeled onto the N-terminus of
the peptide using restrained molecular dynamics and minimization
in which the N-terminus of the peptide was allowed to move, while
the remainder of the protein complex was restrained using a
harmonic potential [54]. The coordinates of this starting structure
are provided as supporting information (Text S2).
An 8 A ˚ shell around the peptide hexamer was used as the input
structure to K. The CFTR C-terminal residues, VQDTRL, were
mutated to the following residues during the design search: P{5 to
W, P{4 stayed fixed to Q, P{3 to all amino acids except Pro, P{2
to T/S, P{1 to all amino acids except Pro, and P0 to I/L/V. In
addition, the Probe program [55] was used to determine the side-
chains on CAL that interact with the CFTR peptide mimic. The
nine residues that interact with the peptide, as well as the two most
N-terminal residues on the peptide, were allowed to be flexible
during the design search (Fig. 1A). To explore the feasibility of our
new algorithms, unless otherwise noted, full partition functions
were not computed and a maximum of 103 conformations were
allowed to contribute to each partition function.
Rotamer values were taken from the Penultimate Rotamer
Library modal values [14]. The energy function used to evaluate
protein conformations has been previously described [40,42]. The
energy function, E~vdWzCoulzEEF1, consists of a van der
Waals term, a Coulombic electrostatics term, and an EEF1 implicit
solvation term [56]. The EEF1 solvation term implicitly models
water solvent during all of the computational designs. All design runs
used the Amber98 [57] forcefield terms except for one prospective
design run which used the Charmm19 [58] forcefield parameters.
Training of Energy Function Weights
Previously-determined experimental binding constants [59]
for 16 of CAL’s natural ligands were used to train the energy
function weight parameters (See Text S1 Section S2). K
scores were computed for each of the natural ligands. For
this training, the CAL-CFTR structure only included the four
most C-terminal residues of the peptide inhibitor. A gradient
descent method was used to optimize the correlation between
the K scores and the experimental K{1
i values. The final
parameters chosen for the design runs are as follows: a van der
Waals scaling of 0.9, a dielectric constant of 20, and a solvation
scaling of 0.76.
Peptide Array Comparison
K was used to predict binding between the CAL PDZ domain
and the HumLib set of 6223 human protein C-termini. The
binding of the C-termini peptides to CAL was experimentally
assessed using a peptide SPOT array [59,60]. Due to experimental
restrictions, all cysteines in the HumLib peptide set were replaced
by serine in the peptide array. For consistency, all computational
predictions compared to the array modeled serines in the place of
cysteines. A summary of the peptide array data is presented in
Fig. 3 while the complete binding results from the array are
provided as Supporting Information (Table S1). The K
algorithm was used to evaluate 4-mer structural models of 6223
peptide-array sequences to verify the accuracy of the algorithm’s
predictions. To compare the array data with the K predictions,
the quantitative array data, measured in biochemical light units
(BLUs), was converted into a binary yes/no CAL binding event. In
other words, by using a fixed cutoff value, each sequence from the
array was classified as either a CAL binder or non-binder. The
cutoff value was chosen as three standard deviations away from the
average BLU value of the array. A receiver operating curve
(ROC), which uses a floating cutoff to compare array data to K
scores, was used to evaluate the ability of K to predict the array
binding data.
After the K predictions were calculated, the binding of C-
termini peptides to CAL was also experimentally assessed using an
additional SPOT array. The profile library array (ProLib; Fig. S3
in Text S1) was designed based on the following motif: bbbb
B{3B{2B{1B0 (B=permutation of a defined set of amino acids,
b=mixture of 17 amino acids, without C, M and W). The defined
set of amino acids were selected based on the HumLib results
combined with substitutional analyses [60] with B{3 =A/C/D/
E/F/I/K/L/M/N/Q/R/S/T/V/W/Y, B{2 =S/T, B{1 =A/
C/D/E/F/I/K/L/M/N/Q/R/S/T/V/W/Y, B0 =I/L/V (To-
tal number of peptides=1734+22 internal control sequences).
Incubation condition: 10mg=ml His-tagged CAL PDZ domain
detected by anti-His (Sigma; 1:2600)/anti-mouse-HRP (Calbio-
chem; 1:2000) antibody sandwich.
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K was used to search over all peptide sequences within the
CAL PDZ domain sequence motif (excluding prolines) to find new
CAL peptide inhibitors. For computational efficiency the number
of conformations enumerated by A* for each partition function
was limited to 103 conformations. Two sets of peptides (promising
designs and poorly ranked designs) were chosen to be experimen-
tally validated.
In order to choose the most promising peptide inhibitors, a
second K design was done where K scores for the top 30
sequences were re-calculated with the number of enumerated
conformations per partition function increased to 105. Several top-
ranked sequences were chosen to be experimentally tested. First,
the top 7 ranked sequences from the second run were chosen. In
addition, two sequences that greatly increased in ranking from the
first to second run (rank 29 to 9, and rank 28 to 11) were chosen as
well. Finally, a K run was conducted using Charmm forcefield
parameters instead of Amber parameters. Two sequences that
scored high on both the Amber and Charmm runs were chosen to
be experimentally tested as well (Table 1).
The poorly-ranked designs were chosen to minimize the
sequence similarity among the set of poorly-ranked peptides
(Table 2). First, the worst-ranked peptide was chosen and added to
initialize the set of negative sequences. Next, sequences were
successively chosen from the worst 200 K ranked sequences and
added to the set in order to maximize the amino acid sequence
diversity with all the sequences already in the set. The similarity
between two sequences was determined using the PAM-30
similarity matrix [61]. In total 23 (eleven top-ranked and twelve
poorly-ranked) K
*-computed peptide inhibitor sequences were
experimentally tested.
Measuring Peptide Inhibitor Constants
The inhibitor dissociation constants of top- and poorly-ranked
peptide sequences from the K CAL-CFTR design were
experimentally determined. As a control, the best known peptide
hexamer was also retested. The corresponding N-terminally
acetylated peptides were purchased from NEO BioScience
(Cambridge, MA) and the Ki values for the peptides were detected
using fluorescence polarization (FP), using the method previously
described in [59]. Briefly, the CAL PDZ domain was incubated in
Figure 3. Summary of CAL peptide array. (A) Summary statistics
for peptide array. Higher BLU (biochemical light unit) values indicate
stronger protein binding to a peptide. (B) Distribution of the peptide
BLU values from the peptide array in units of standard deviation above
the mean (s). (C) Normalized amino acid frequencies for the top
sequences that have a BLU value greater than 3 standard deviations
from the average, which were considered as the peptides that bound
CAL for the validation of K predictions. The frequency of each amino
acid type for each residue position was normalized by the total number
of occurrences of that amino acid in the array at the given residue
position.
doi:10.1371/journal.pcbi.1002477.g003
Table 1. Experimental validation of top-ranked K
predictions.
Name Sequence K Ranking Experimental
(out of 2166) Ki (mM)
kCAL01 Ac-WQVTRV 9 2:3+0:2
{
kCAL02 Ac-WQFTRL 1
{ 7:6+0:7
{
kCAL03 Ac-WQKTRL 2 9:0+0:6
{
kCAL04 Ac-WQRTRL 5 10:8+0:7
{
kCAL05 Ac-WQKTRI 4 12:0+0:9
{
kCAL06 Ac-WQKTRV 1 16+2
kCAL07 Ac-WQFTKL 2
{ 16+1
kCAL08 Ac-WQRTRI 7 16+2
kCAL09 Ac-WQLTKL 11 17+1
kCAL10 Ac-WQKTKL 6 17:8+0:8
kCAL11 Ac-WQRTRV 3 18+1
{Ki values with a binding affinity higher than the best previously known
hexamer (14+1mM). These sequences are shown in green in Fig. 5.
{Sequence rank obtained by ordering the quantity:
RAzRC
2
, where RA is the
sequence rank from a design run using the Amber forcefield and RC is the
sequence rank from a run using the Charmm forcefield.
doi:10.1371/journal.pcbi.1002477.t001
Table 2. Experimental validation of poorly-ranked K
predictions.
Name Sequence K Ranking Experimental
(out of 2166) Ki (mM)
kCAL20 Ac-WQYTMI 1981 24+4
kCAL21 Ac-WQYTDL 2082 32+4
kCAL22 Ac-WQISWL 1973 37+15
kCAL24 Ac-WQHTEV 1989 87+7
kCAL23 Ac-WQMTDI 1969 90+9
kCAL25 Ac-WQCSEI 2051 107+9
kCAL26 Ac-WQESEL 2095 120+20
kCAL27 Ac-WQDTWI 2158 400+20
kCAL28 Ac-WQWSDV 2166 400+200
kCAL29 Ac-WQDSCV 2011 1000+200
kCAL30 Ac-WQGSDV 2075 2200+300
kCAL31 Ac-WQDSGI 1992 w5000
doi:10.1371/journal.pcbi.1002477.t002
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ed to a final concentration of 0.1 mg/mL bovine IgG (Sigma) and
0.5 mM Thesit (Fluka)) with a labeled peptide of known binding
affinity. Each peptide inhibitor was serially diluted and the
protein-peptide mixture was added to each dilution. Finally, the
amount of competitive inhibition was tracked using residual
fluorescence polarization at temperatures between 25{280C.
Each Ki value is reported as an average of three FP experiments
conducted on separate days along with the corresponding standard
deviation.
Measuring Chloride Flux
Ussing chamber experiments were performed as described
previously [11]. Polarized monolayers of patient-derived bronchial
epithelial cells, CFBE-DF cells (a generous gift of Dr. J.P. Clancy
[62,63]), were maintained in MEM with 2 mM l-glutamine, 10%
fetal bovine serum, 50 units/mL penicillin, 50mg=mL streptomy-
cin, 2mg=mL puromycin, 5mg=mL plasmocin, and 2:5mg=mL
amphotericin B. Cells were grown at 370C in 5% CO2. Twenty
four hours before treatment the cells were moved to MEM with
only penicillin and streptomycin. Peptides were dissolved in
DMSO and diluted to 500mM in PBS. Peptide solutions were
applied to cells following incubation with BioPORTER delivery
reagent (Sigma). The final DMSO concentration did not exceed
0.03%. Following a 3.5 hour incubation with peptide, short circuit
currents (ISC) were monitored in Ussing chambers. Following
treatment with amiloride, forskolin, and genistein, DF508-CFTR
chloride flux was measured as the change in ISC when the CFTR-
specific inhibitor, CFTRinh172 [64,65], was applied to the cell
monolayer. All measurements were performed at 370C.
Results
We applied the K algorithm to the CAL-CFTR system to find
a CAL PDZ peptide inhibitor that acts as a biologically active
stabilizer of DF508-CFTR. First, we developed the ensemble-
based computational structural design software K to design PPIs.
To validate the design methodology, the predictions of the K
algorithm were compared with binding data of CAL binding
human protein C-termini. The validation showed K was able to
enrich for peptide inhibitors. We then used K to prospectively
find new peptide inhibitors of CAL. The top-scoring predicted
sequences were experimentally validated and we determined that
they all bind CAL with mM affinity. Next, additional binding data
for peptide sequences that match the known CAL binding motif
were collected and compared to the K predictions. Finally,
Ussing chamber experiments showed that the highest affinity
designed peptide significantly rescues DF508-CFTR in bronchial
epithelial cells.
Validation of the K Algorithm
To validate the K algorithm, we compared K predictions for
CAL peptide inhibitors against peptide array binding data. First,
peptides from the 6223 peptide HumLib library were tested for
CAL binding using a SPOT array [59]. The array was able to find
over one hundred peptides that clearly bind the CAL PDZ domain
(Fig. 3). Second, K predictions were made for all of the peptide
sequences in the HumLib library. Fig. 4A shows the resulting
receiver operating curve (ROC) when comparing the K scores to
the binding measurements (BLU values) of the peptide array. The
ROC has an area under the curve (AUC) of 0.84 which shows that
K greatly enriches for peptides that bind CAL. Specifically,
according to the peptide array, out of the top 30 K predicted
sequences, 11 are expected to bind CAL. Notably, this is a 20-fold
increase over the number of binders that would be expected to be
found if the CAL binding peptides were distributed randomly
within the K predictions.
To investigate the success of the algorithm in more detail, we
evaluated the importance of the CAL binding motif in
determining K predictions. The amino acid frequencies from
the top binding peptides of the HumLib library (Fig. 3C) and
natural binding partners of CAL [59] reveal that the canonical
sequence motif of CAL is X-S/T-X-L/V/I. As expected, among
the full set of HumLib peptides, K enriches for sequences that
conform to this motif. Furthermore, if we allow K to design
peptides varying at the primary motif positions 0 and 22, it
achieves an AUC of 0.94 (Text S1 Section S3 and Fig. S2 in Text
S1), confirming its ability to identify the motif de novo. While K
also identified a few non-motif sequences in each case, the
HumLib suggests that CAL actually can bind to such sequences,
albeit less frequently (10 of 5867 sequences).
Of course, the identification of motif residues, while a necessary
test of the algorithm, does not by itself represent a major advance
in affinity prediction. The HumLib library shows that only 70 out
of 261 sequences with the CAL binding motif bind to CAL. A
much more stringent test of the K design algorithm is thus to
determine how well K enriches for binders among sequences that
match the known CAL binding motif. As a first test, we
recalculated the ROC curve considering only peptides in the
HumLib library that match the CAL sequence motif, and K was
still able to significantly enrich for CAL peptide binders
(AUC=0.71; Fig. 4B). This search, together with the blind test
of K rankings described below, provides a true test that the
success of K in predicting HumLib binders is not merely due to
its identification of peptides conforming to the known sequence
motif, but also to its ability to distinguish high- and low-affinity
binders among such peptides.
Figure 4. K enriched for peptide sequences that bind the CAL
PDZ domain. ROCs were calculated comparing K predictions to (A)
the entire HumLib peptide array data set (AUC=0.84) and (B) only
sequences in the HumLib array that matched the CAL binding motif
(AUC=0.71).
doi:10.1371/journal.pcbi.1002477.g004
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While SPOT arrays have proven to be a powerful tool for the
identification of CAL binding peptides, the highest affinity
inhibitors identified to date are composed of at least 10 amino
acids. For hexamers, the highest published affinity is for iCAL35
(WQTSII; [60]). Since K was able to successfully enrich for CAL
binders found in the HumLib library, we then used K to
prospectively find novel, shorter CAL peptide inhibitors, searching
over 2166 peptides containing motif-based combinations of the C-
terminal four residues. To facilitate accurate experimental
binding-constant measurements, each peptide was extended by a
shared N-terminal addition of the most frequent P{5 and P{4
residues among HumLib binders(WQ), yielding hexamer sequenc-
es that exhibit a higher baseline affinity [59]. Both top- and
bottom-ranked sequences were chosen for experimental valida-
tion. The Ki value for each peptide hexamer was determined using
fluorescence polarization [59] (Table 1). We used the same FP
protocol to confirm the affinity of the acetylated iCAL35 reference
peptide for CAL (Ki~14+1mM).
All of our top-ranked inhibitors are novel CAL ligands, for which
neither predicted nor experimental affinities were previously
available. Remarkably, all of the top predicted peptides bind CAL
with high affinity (Fig. 5A, Table 1). The tightest binding predicted
peptide (kCAL01, WQVTRV) had a Ki of 2:3+0:2mM. While this
affinity is comparable to that of several other PDZ inhibitors [66,67],
solution-state measurements show that the CAL PDZ domain
exhibits systematically weak interactions with target C-termini: note
that the Ki for the wild-type CFTR sequence (TEEEVQDTRL)
is 390mM and the best known affinity natural ligand
(ANGLMQTSKL) for CAL is 21mM [60]. Thus, our design
algorithm successfully identifies high affinity peptide inhibitors of the
CAL PDZ domain, with 170-fold higher affinity than the interaction
we were trying to inhibit and 9-fold higher affinity than any
comparable natural ligand. This peptide affinity advantage may be
important in physiological applications, since the native CAL:CFTR
target interaction may involve additional sources of affinity outside
the PDZ binding pocket [4,59], not available to a peptide inhibitor.
We also performed further analysis of the HumLib SPOT array
used for K validation. Selecting the most common amino acid at
positions P0 to P{5 among HumLib binders yields the sequence
WQSTRL (HumLib01, Fig. 3C), which is ranked in the top 50 K
predictions (out of 2166). This sequence is also the strongest binder
identified among the ProLib sequences (see below, and Fig. S3 in
Text S1). However, when we measured the CAL binding for
HumLib01 using fluorescence polarization (FP) it exhibited a Ki
value of 13:5+0:5mM, only a marginal improvement in affinity
compared to iCAL35 (14+1mM). In comparison, five of the
eleven top K predicted sequences we measured with FP show an
improvement in binding compared to both iCAL35 and
HumLib01, and kCAL01 shows a six-fold improvement over
both iCAL35 and the HumLib01 sequence.
The best inhibitor found through previous FP and array screens
involves a fluorescein group modification to a peptide decamer (F
*-
iCAL36, F
*-ANSRWPTSII, Kd~1:3mM). kCAL01 rivals this
binding affinity despite the computational search library restriction
to only allow amino acids and hexamer sequences. Critically, at
830 Da, kCAL01 has approximately twice the binding efficiency
(ratio of inhibitor potency, DG, to molecular mass) of F
*-iCAL36
and is much closer in size to typical drugs. This makes kCAL01 a
very promising inhibitor compared to F
*-iCAL36 and other
discovered inhibitors.
Furthermore, as suggested by our retrospective tests, the tight
binding of our top-ranked sequences was not merely a conse-
quence of the underlying CAL-binding motif used to select
candidate sequences for evaluation. To establish this, we selected a
set of poorly-ranked peptides to minimize sequence similarity and
evaluated their CAL-binding affinity experimentally. Almost all of
the poorly-ranked sequences bound CAL, consistent with their
motifs (Fig. 5A). Reflecting the enrichment of CAL binders in the
pool, the two poorly-ranked peptides with the best affinities
(Ki~24mM and 32mM, respectively) were indeed close to the
affinity of the weakest top-ranked sequence (Ki~18mM). Howev-
er, all of the poorly ranked peptides bound CAL more weakly than
any of the top-ranked sequences (Table 1), and none of them had
Figure 5. (A) DG values for top- and poorly-ranked K predictions that were experimentally tested using fluorescence polarization.
Predictions plotted in green denote that the binding affinity was higher than the best previously known hexamer (14 mM). Horizontal line represents
average DG for plotted sequences. Sequence information and binding data can be found in Tables 1 and 2. (B) Ensemble of top 100 conformations
for the peptide (kCAL01: WQVTRV, orange sticks) with tightest binding to CAL (gray ribbon).
doi:10.1371/journal.pcbi.1002477.g005
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suggests that K can efficiently distinguish among motif-bearing
peptides, allowing it to predict sequences with CAL affinities
unprecedented among hexamers.
Detailed analysis of the K predictions suggests that the use of
both ensemble-weighting and minDEE approaches was important
in the success of the algorithm. The ensembles generated by K do
not have a dominant conformation, i.e., a conformation with
significantly lower energy than the others, which would thus
dominate in the partition function. For example, in the case of
iCAL35 (WQTSII), K found 75 conformations that were within
0.5 kcal/mol and 454 conformations that were within 1 kcal/mol
of the iCAL35 GMEC. In general, the ensemble conformations
are consistent with canonical PDZ:peptide interactions and with
the conformation of the CAL-bound CFTR peptide determined
by NMR [52]. To determine the importance of the ensemble-
based K rankings we compared the predictions to two single-
structure GMEC-based methods, minDEE [41], and rigid-
rotamer DEE (rigidDEE) [68]. Both minDEE and rigidDEE were
run with the same energy parameters as the K designs. However,
since the single-structure designs only compute the energy of the
bound state, reference energies [16] were included as in [69] to
account for the energy of the unbound state. The inclusion of
reference energies for single-structure designs have been deemed
necessary by most protein designers to account for the unfolded/
unbound state [24,69,70]. K does not need reference energies
since it calculates a partition function for both the bound and
unbound states of the complex [16,40]. Therefore, reference
energies are included to make the comparison between K and the
single-structure designs more fair. We compared the top 30
sequences from minDEE and rigidDEE and found they had no
sequences in common. This supports previous work where we
have shown that in over 69 protein design systems minDEE finds
low energy sequences that rigidDEE discards by not allowing
minimization [41,50]. In addition, when we compare the top 30
rigidDEE and minDEE results to the top K designs we find that
they have only three and four sequences in common, respectively.
If we had used only GMEC-based approaches instead of K,w e
would not have predicted most of the experimentally successful
sequences that K found, including the best inhibitor kCAL01. In
addition, the overall sequence rankings show a very poor
correlation between the minDEE and K predictions; the same
is true of the rigidDEE and K predictions (R2 =0.1 and 0.09
respectively).
Blind Test of K Predictions within the CAL Binding Motif
The prospective peptide predictions demonstrate that K can
successfully find CAL peptide inhibitors. Our solution-state
binding tests provide robust information for the best and worst
K
*-predicted peptides, but give little information about the CAL
binding of the remaining peptides that match the CAL motif. To
investigate this experimentally, we designed a peptide library
SPOT array (ProLib) based on the HumLib motif combined with
substitutional analyses [60]. The resulting sequences closely match
our prospective prediction set and the binding of these sequences
to CAL was assessed as described in the Materials and Methods
section. Using a similar analysis to that performed on the HumLib
peptide array we compared the K predictions to the CAL binding
observed with the ProLib array. We found an AUC=0.88 (Fig. 6).
Note that this AUC is much higher than the 0.71 found when only
looking at CAL motif sequences within the HumLib array. One
explanation for this improvement is that the experimental setup is
closer to the design model used by K. Specifically, the ProLib
array uses a mixture of amino acids at P{4 to P{7 of the peptides,
while the HumLib array is composed of decamer peptides. Thus,
the ProLib data focuses on the identity of the last 4 C-terminal
positions, which better matches the sequence and structure search
space of the K designs. A complete evaluation of the accuracy of
K affinity predictions would require the synthesis and FP binding
analysis of all 2166 sequences within the CAL binding motif.
However, taken together, the FP measurements for the designed
peptides plus the ProLib blind test suggest that K is a powerful
filter, efficiently selecting tight binders from a pool of sequences
with baseline affinity for the target.
Biological Activity of the Highest Affinity Designed
Peptide Inhibitor
All of our top-predicted inhibitors successfully bound CAL,
which suggests that they should disrupt the degradation pathway
of CFTR. The ability of kCAL01 to restore DF508-CFTR
function was assessed by measuring CFTR-mediated chloride
efflux in CF-patient derived bronchial cells expressing DF508-
CFTR (CFBE-DF) using an Ussing chamber apparatus [11]. As a
control peptide, we used kCAL31 (WQDSGI), which was ranked
as the weakest interactor by K and for which no binding was
detected experimentally (Table 2). Fig. 7 shows DF508-CFTR
chloride secretion across polarized monolayers treated with either
kCAL31, the iCAL35 reference peptide, or kCAL01. Previous
studies with fluorescently labeled peptides have demonstrated
delivery into CFBE-DF cells using the BioPORTER reagent [11].
Significance of rescue was evaluated by comparing percentage
improvement in chloride efflux to rescue from a well-established
‘‘corrector’’ under identical conditions, and by Student’s t-test (p-
value). Compared to the non-binding control, the previously best
hexamer, iCAL35, yields only a slight (non-significant) improve-
ment in chloride secretion (4%, p~0:16). In contrast, chloride
secretion following treatment with the designed inhibitor kCAL01
is significantly enhanced with respect to the control peptide (12%,
p~0:0049) and with respect to the reference (8%, p~0:037)
peptide. Indeed, the biological activity of kCAL01 is very similar to
that observed under similar conditions following treatment with
either the best previously available CAL inhibitor (F
*-iCAL36) or
the first-generation corrector corr-4a [6,11].
Figure 6. K was used to predict binding between the CAL PDZ
domain and the peptide array, ProLib (Figure S3), which
contained peptide sequences that match the CAL binding
motif. The ROC curve shown compares the K predictions to the
observed peptide array binding data. AUC=0.88.
doi:10.1371/journal.pcbi.1002477.g006
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The new K algorithm has enabled the design of the first high-
affinity hexapeptide CAL PDZ inhibitor with demonstrated ability
to rescue DF508-CFTR. By interfering with CAL-mediated
degradation, our best designed peptide, kCAL01, can act as a
CFTR ‘‘stabilizer,’’ allowing DF508-CFTR to recycle back into
the membrane. Currently the only well-studied ways to rescue
mutant CFTR function with drug-like molecules are through
‘‘potentiators’’ and ‘‘correctors’’ which do not address the problem
that DF508-CFTR is rapidly endocytosed and degraded at
physiological temperatures [9]. Like other CAL inhibitors,
kCAL01 should work in conjunction with potentiators and
correctors to create an additive effect [11].
kCAL01 was observed to increase DF508-CFTR activity by
12%. While this effect is clearly statistically significant (p~0:0049),
we also wished to assess its magnitude relative to the effect of
known rescue compounds. The performance of kCAL01 was
benchmarked using polarized human airway epithelial cells
derived from a CF patient (stably expressing DF508-CFTR;
CFBE-DF cells). In these cells, CFTR rescue is more challenging
than in heterologous cells, but the levels of rescue observed are
more likely to reflect the physiological situation. Since CFTR
modulation is extremely sensitive to experimental conditions, and
particularly to the type of cells used [8,71], we chose to compare
the performance of kCAL01 against the corrector corr-4a. There
are two reasons for this choice for comparison: (a) corr-4a is a well
established benchmark for CFTR correctors [72]; and (b) directly
comparable data are available based on our previous studies [1].
Under identical experimental conditions, corr-4a produces a 15%
increase in DF508-CFTR levels in CFBE-DF cells [1]. Thus, the
12% increase seen with the kCAL01 inhibitor peptide is similar to
that produced by a first-generation corrector. Since corr-4a and
kCAL01 have orthogonal mechanisms of action, this enables
additive rescue as an attractive treatment option. Specifically, in
the long term the therapeutic impact of CAL inhibitors is likely to
be enhanced by their ability to provide additive rescue with
correctors, offering the prospect of combination treatment [11].
To design kCAL01 we developed a novel, provable, ensemble-
based protein design algorithm for protein-peptide and protein-
protein interactions. The validation of K by comparing its
predicted binding scores to CAL peptide-array data demonstrates
K’s strong ability to enrich for human protein sequences that
bind CAL. While the HumLib array showed that CAL binds a
specific motif, it also shows (along with the ProLib array) that CAL
does not bind all sequences that match the motif. In HumLib, 191
of 261 sequences that match the motif did not bind CAL.
Moreover, all of the peptides synthesized for this work (kCAL01-
kCAL31) match the CAL motif, but have a wide range of binding
affinities. Therefore, K needs to perform the difficult task of
differentiating the affinities of peptides that share the CAL motif,
rather than merely separating motif from non-motif sequences.
The HumLib analysis, FP analysis of top and poorly-ranked K
predictions, and the ProLib analysis all show that K is able to
enrich for sequences within the CAL PDZ sequence motif that
have high-affinity interactions with CAL.
The experimental validation of top-ranked K sequences
confirms that K prospectively predicted novel high-affinity CAL
peptide inhibitors. Compared to the inhibitory constant of the
natural CFTR C-terminus, the designed sequences are much
stronger binders. Indeed, our approach found peptide sequences
that bound more tightly than iCAL35, the best previously known
hexamer sequence. Interestingly, even though iCAL35 binds to
the CAL PDZ domain, it is unable to mediate significant or
substantial rescue of DF508-CFTR in CFBE-DF cells (Fig. 7). The
designed inhibitor’s improvement in binding directly translates to
increased DF508-CFTR activity in CF-patient derived airway
epithelial cells, demonstrating the value of using our computa-
tional approach to design protein:peptide interactions.
Current therapeutics known to rescue CFTR function are small
molecules generally discovered through high throughput library
screens [72]. To find CFTR stabilizers we needed to discover
inhibitors that could block the CAL-CFTR PPI. Unfortunately,
small molecules that inhibit PPIs are rare and the development of
such inhibitors has been very difficult due to the shallow,
distributed nature of the interfaces [73]. Therefore, we have
focused on tools to design peptide inhibitors, developing and
validating a new K algorithm that has identified low molecular
weight, high-affinity sequences. While our previous work em-
ployed high-throughput peptide arrays to screen for inhibitors
[60], the computational design approach can easily and accurately
be expanded beyond the limits of peptide array synthesis,
providing a novel avenue for identifying CF therapeutic leads
with improved affinity, specificity, and proteolytic stability.
In this paper we have focused on improving peptide inhibitor
affinities, but our success suggests that K can also be used to
improve peptide specificity and proteolytic stability. For optimal
biological efficacy, CAL inhibitors should avoid off-target effects,
including interactions with other CFTR trafficking proteins (Fig 1B),
such as the NHERF family [3]. To achieve peptide specificity, K
could be run to find peptides that did not bind wellto these off-target
interactors, a process known as negative design [16,42]. The
experimentally-tested poorly-ranked K predictions all had a worse
affinity for CAL than the top-predicted peptides (Tables 1 and 2).
This suggests that K has the capability to conduct negative design
for the CAL system. Also, we have shown the successful application
of K negative design to other biological systems [42]. Finally, since
theefficacyofnaturalpeptidesisoftenlimitedbyproteolyticstability,
it could be beneficial to extend the K software to incorporate non-
natural amino acids, such as d-amino acids, into the design search
space. This willallow the design of compounds that inhibit CAL, but
cannot be degraded as readily as linear L-peptides.
Figure 7. Top binding peptide is biologically active. The DF508-
CFTR specific chloride flux is shown for a control peptide (kCAL31;
WQDSGI; no CAL binding detected), the reference peptide (iCAL35;
WQTSII), and the tightest binding design peptide (kCAL01; WQVTRV).
kCAL01 shows a 12% increase in chloride efflux over the control
peptide. p values shown are for pairwise comparisons (n~12). Values
shown are mean + standard error of the mean (SEM). N.S.: not
significant, p~0:16.
doi:10.1371/journal.pcbi.1002477.g007
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der Waals energy, and implicit solvation. K also utilizes an
approximation of conformational entropy factors through its
ensemble-based scoring [16,41]. Analysis of these components can
potentially identify important interactions in the top peptide inhibitor
designs. Comparing the average energy contribution for the top 30
predictions to the median for all designs we find that all components
contribute favorably to the peptide binding, with van der Waals
giving the largest benefit (211.2 kcal/mol), followed by electrostatics
(210.9 kcal/mol), and finally solvation (28.2 kcal/mol). However,
evenwithin thetop30predictionsthedominantenergeticcomponent
varies greatly (electrostatics is dominant for 12 sequences, van der
Waals for 6 sequences, and solvation for 12 sequences).
Tidor and co-workers [69] have suggested that design
predictions are best when re-ranking structures using a purely
electrostatic energy function. We addressed this possibility by
comparing the AUC obtained from a purely electrostatic function
vs. that obtained from our complete energy function. If we use
only the electrostatic term, the AUC was 0.61 (bound energy only)
or 0.66 (bound minus unbound). Both values are significantly
lower than the 0.84 AUC value obtained with the full function.
Thus, while electrostatic terms are important to the success of the
algorithm, inclusion of a more complete energetic model improves
the prediction. In fact, no individual energy term outperforms the
K score when classifying the peptide array data. Thus, K
predicts its successful designs by accurately incorporating all three
energy terms through ensemble-based scoring.
Many of the binding sequences identified by K contain a
positively charged residue (R/K) at P{1. Similarly, in the HumLib
array, about 26% of the sequences that we consider to be binders
contain a positively charged residue at P{1, and in the ProLib
array 53% of the binders contain an R/K at P{1. Based on our
previous NMR analysis [52], the P{1 Arg can form a salt-bridge
with Glu309 on the periphery of the CAL binding site (Fig. 1A), an
electrostatic contribution that could theoretically dominate the
ROC curve analysis. However, because 74% of the top binding
sequences in the HumLib array do not contain the P{1 R/K, the
strong K AUC values suggest that it must also correctly predict
these sequences. To test this assertion more forcefully, we removed
all of the sequences with a positively charged residue at position
21 and then recalculated the ROC curve. This results in an AUC
of 0.82, almost identical to the value of 0.84 obtained with all
sequences. Thus, consistent with the significant contributions of
each term in the energy function, the ROC behavior of the
algorithm is not dependent on the presence or absence of a
positively charged residue at P{1.
A small number of Ki values were used to train the new K
algorithm to properly scale energy terms for protein-peptide
interactions, which can now be used for additional protein-peptide
interaction designs. Besides the training, the only system specific
data used was the input starting structure and CAL sequence
motif. The sequence motif was used as an optional filter to
expedite the search, but should not affect the ability of K to find
high-affinity inhibitors. As seen from the HumLib peptide array
comparison, K yields a higher ROC AUC when considering the
entire array, which implies that K is better at distinguishing CAL
peptide inhibitors from the entire sequence space than from within
only the known sequence motif. This suggests K will be able to
find new high-affinity inhibitors if the search space is expanded.
Beyond its utility in the design of enhanced CAL inhibitors, the
K algorithm represents a general framework for analyzing PDZ
domains and other protein-protein interfaces. PDZ domains are
among the most common interaction domains in the human
genome [74]. Using traditional biochemical approaches, the
characterization of the binding affinity of candidate partners, as
well as the identification of high-affinity reporters and inhibitors,
often requires the individual synthesis of dozens of peptides, many
of which fail to interact robustly. As shown for CAL, K offers a
facile mechanism to predict affinities and to design novel ligand
sequences using only an initial input structure. Furthermore, the
proofs and algorithm presented here provide a general approach
for modeling peptide-mediated PPIs that regulate a wide variety of
critical physiological processes.
Availability
The source code of our program is freely available, and is
distributed open-source under the GNU Lesser General Public
License (Gnu, 2002). The source code can be freely downloaded at
http://www.cs.duke.edu/donaldlab/osprey.php.
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